Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. August 2018 16:20 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update

CORAL GABLES, Fla., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
06. August 2018 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Expands Commercial Leadership Team

CORAL GABLES, Fla., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
01. August 2018 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Hold Second Quarter Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 8th, 2018

CORAL GABLES, Fla., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
13. Juni 2018 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer

CORAL GABLES, Fla., June 13, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
31. Mai 2018 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

CORAL GABLES, Fla., May 31, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
29. Mai 2018 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse® (Amifampridine Phosphate) for Lambert-Eaton Myasthenic Syndrome

CORAL GABLES, Fla., May 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
09. Mai 2018 16:13 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and Provides Corporate Update

CORAL GABLES, Fla., May 09, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
02. Mai 2018 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Hold First Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, May 10th, 2018

CORAL GABLES, Fla., May 02, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
24. April 2018 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Introduces New Corporate Website

CORAL GABLES, Fla., April 24, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
19. April 2018 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis

CORAL GABLES, Fla., April 19, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...

Vorherige Seite

Nächste Seite